-
Posted by
Two Blokes Jun 21 -
Filed in
Stock
-
4 views
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic\u00ae) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile.
